Search

Your search keyword '"Aapro, M"' showing total 1,280 results
Start Over Author "Aapro, M"
1,280 results on '"Aapro, M"'

1. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents.

Author

Herrstedt, Jørn, Celio, L, Hesketh, P, Zhang, L, Navari, R, Chan, A, Saito, M, Chow, R, and Aapro, M

Subjects
Antiemetics, Guideline, HEC, High-emetic-risk chemotherapy, Nausea, Vomiting, Female, Humans, Emetics, Antiemetics, Consensus, Olanzapine, Nausea, Vomiting, Antineoplastic Agents, Cyclophosphamide, Anthracyclines
Abstract

PURPOSE: This systematic review updates the MASCC/ESMO recommendations for high-emetic-risk chemotherapy (HEC) published in 2016-2017. HEC still includes cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, and cyclophosphamide in doses of > 1500 mg/m2 and the combination of cyclophosphamide and an anthracycline (AC) in women with breast cancer. METHODS: A systematic review report following the PRISMA guidelines of the literature from January 1, 2015, until February 1, 2023, was performed. PubMed (Ovid), Scopus (Google), and the Cochrane Database of Systematic Reviews were searched. The literature search was limited to randomized controlled trials, systematic reviews, and meta-analyses. RESULTS: Forty-six new references were determined to be relevant. The main topics identified were (1) steroid-sparing regimens, (2) olanzapine-containing regimens, and (3) other issues such as comparisons of antiemetics of the same drug class, intravenous NK1 receptor antagonists, and potentially new antiemetics. Five updated recommendations are presented. CONCLUSION: There is no need to prescribe steroids (dexamethasone) beyond day 1 after AC HEC, whereas a 4-day regimen is recommended in non-AC HEC. Olanzapine is now recommended as a fixed part of a four-drug prophylactic antiemetic regimen in both non-AC and AC HEC. No major differences between 5-HT3 receptor antagonists or between NK1 receptor antagonists were identified. No new antiemetic agents qualified for inclusion in the updated recommendations.

Published
2023

3. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

Author

Herrstedt, J., Clark-Snow, R., Ruhlmann, C.H., Molassiotis, A., Olver, I., Rapoport, B.L., Aapro, M., Dennis, K., Hesketh, P.J., Navari, R.M., Schwartzberg, L., Affronti, M.L., Garcia-Del-Barrio, M.A., Chan, A., Celio, L., Chow, R., Fleury, M., Gralla, R.J., Giusti, R., Jahn, F., Iihara, H., Maranzano, E., Radhakrishnan, V., Saito, M., Sayegh, P., Bosnjak, S., Zhang, L., Lee, J., Ostwal, V., Smit, T., Zilic, A., Jordan, K., and Scotté, F.

Published
2024
Full Text
View/download PDF

7. Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life

Author

Epstein RS, Basu Roy UK, Aapro M, Salimi T, Moran D, Krenitsky J, Leone-Perkins ML, Girman C, Schlusser C, and Crawford J

Subjects
cancer, chemotherapy, myelosuppression, real world, quality of life, patient burden, Medicine (General), R5-920
Abstract

Robert S Epstein,1 Upal K Basu Roy,2 Matti Aapro,3 Tehseen Salimi,4 Donald Moran,4 JoAnn Krenitsky,1 Megan L Leone-Perkins,5 Cynthia Girman,6 Courtney Schlusser,7 Jeffrey Crawford8 1Epstein Health, LLC., Woodcliff Lake, NJ, USA; 2LUNGevity Foundation, Bethesda, MD, USA; 3Clinique De Genolier, Genolier, Switzerland; 4G1 Therapeutics Ltd., Research Triangle Park, NC, USA; 5HealthiVibe, a Division of Corrona, LLC., Arlington, VA, USA; 6Chapel Hill Consulting, LLC., Chapel Hill, NC, USA; 7UNC Gillings School of Global Public Health, Chapel Hill, NC, USA; 8Duke University Medical Center, Durham, NC, USACorrespondence: Robert S EpsteinEpstein Health, LLC., Woodcliff Lake, NJ, 07677, USATel +1 201-285-5800Email repstein@epsteinhealth.comPurpose: To evaluate which side effects of chemotherapy are considered most burdensome by patients with cancer, identify which health care professionals pay most attention to symptoms associated with chemotherapy-induced myelosuppression (CIM) from the patient perspective, and capture the “patient voice” describing how CIM impacts their daily lives.Participants and Methods: Online survey of participants with breast, lung, or colorectal cancer who had received chemotherapy within the past 12 months and experienced ≥ 1 episode of CIM in the past year. Participants were asked to answer close-ended questions and provide qualitative responses to: “In your own words, please describe how side effects from myelosuppression have impacted your life.”Results: Among 301 survey participants, fatigue was the most frequently reported side effect of chemotherapy; 55% of participants rated fatigue as highly bothersome (9 or 10 on a 1– 10 scale of “bothersomeness”). Participants rated symptoms associated with CIM, including fatigue, weakened immune system (infections), bleeding and/or bruising, and shortness of breath, as being as bothersome as other side effects of chemotherapy, including alopecia, neuropathy, and nausea/vomiting. Overall, 24– 43% of participants thought that CIM and its symptoms had a negative impact on their daily lives, including their ability to complete tasks at home and work, and to socialize. Qualitative responses supported these findings; participants highlighted that CIM-related symptoms, particularly fatigue and fear of infections, affected their ability to be physically active, complete work, or continue meaningful relationships with friends and family.Conclusion: Participants described a real-world impact of CIM that often isolates them from family and friends, and means that they are unable to work or perform tasks of daily living. Using measures that help patients to recognize and communicate the signs and symptoms of CIM might increase the likelihood of maintaining daily lives as close to normal as possible, during and after chemotherapy treatment.Keywords: cancer, chemotherapy, myelosuppression, real world, quality of life, patient burden

Published
2021

11. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Author

Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C.H., Bergh, J., Biganzoli, L., Boers-Doets, C.B., Cardoso, M.J., Carey, L.A., Cortés, J., Curigliano, G., Diéras, V., El Saghir, N.S., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Johnston, S.R.D., Kaufman, B., Koppikar, S., Krop, I.E., Mayer, M., Nakigudde, G., Offersen, B.V., Ohno, S., Pagani, O., Paluch-Shimon, S., Penault-Llorca, F., Prat, A., Rugo, H.S., Sledge, G.W., Spence, D., Thomssen, C., Vorobiof, D.A., Xu, B., Norton, L., and Winer, E.P.

Published
2018
Full Text
View/download PDF

17. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

Author

Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M.J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Kaufman, B., Krop, I., Mayer, M., Meijer, H., Mertz, S., Ohno, S., Pagani, O., Papadopoulos, E., Peccatori, F., Penault-Llorca, F., Piccart, M.J., Pierga, J.Y., Rugo, H., Shockney, L., Sledge, G., Swain, S., Thomssen, C., Tutt, A., Vorobiof, D., Xu, B., Norton, L., and Winer, E.

Published
2017
Full Text
View/download PDF

18. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations

Author

Rapoport BL, Aapro M, Chasen MR, Jordan K, Navari RM, Schnadig I, and Schwartzberg L

Subjects
Rolapitant, neurokinin-1 receptor antagonist, chemotherapy-induced nausea and vomiting, post hoc analyses, Therapeutics. Pharmacology, RM1-950
Abstract

Bernardo Leon Rapoport,1 Matti Aapro,2 Martin R Chasen,3 Karin Jordan,4 Rudolph M Navari,5 Ian Schnadig,6 Lee Schwartzberg7 1The Medical Oncology Centre of Rosebank, Johannesburg, South Africa; 2Breast Center, Genolier Cancer Center, Genolier, Switzerland; 3Palliative Care, William Osler Health Services, Brampton, ON, Canada; 4Department of Medicine V, University of Heidelberg, Heidelberg, Germany; 5Division of Hematology Oncology, University of Alabama School of Medicine, Birmingham, AL, USA; 6Compass Oncology, US Oncology Research, Tualatin, OR, USA; 7West Clinic, Memphis, TN, USA Abstract: Knowledge of the involvement of the neurokinin substance P in emesis has led to the development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of chemotherapy-induced nausea and vomiting (CINV), in combination with serotonin type 3 receptor antagonists and corticosteroids. The NK-1 RA rolapitant, recently approved in oral formulation, has nanomolar affinity for the NK-1 receptor, as do the other commercially available NK-1 RAs, aprepitant and netupitant. Rolapitant is rapidly absorbed and has a long half-life in comparison to aprepitant and netupitant. All three NK-1 RAs undergo metabolism by cytochrome P450 (CYP) 3A4, necessitating caution with the concomitant use of CYP3A4 inhibitors, but in contrast to aprepitant and netupitant, rolapitant does not inhibit or induce CYP3A4. However, rolapitant is a moderate inhibitor of CYP2D6, and concomitant use with CYP2D6 substrates with narrow therapeutic indices should be avoided. Aprepitant, netupitant, and rolapitant have all demonstrated efficacy in the control of delayed CINV in patients receiving moderately and highly emetogenic chemotherapy in randomized controlled trials, including over multiple cycles of chemotherapy. We reviewed recent post hoc analyses of clinical trial data demonstrating that rolapitant is efficacious in the control of CINV in patient populations with specific tumor types, namely, breast cancers, gastrointestinal/colorectal cancers, and lung cancers. In addition, we show that rolapitant has efficacy in the control of CINV in specific age groups of patients receiving chemotherapy (

Published
2017

21. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Author

Vrdoljak, E., Marschner, N., Zielinski, C., Gligorov, J., Cortes, J., Puglisi, F., Aapro, M., Fallowfield, L., Fontana, A., Inbar, M., Kahan, Z., Welt, A., Lévy, C., Brain, E., Pivot, X., Putzu, C., González Martín, A., de Ducla, S., Easton, V., and von Minckwitz, G.

Published
2016
Full Text
View/download PDF

25. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

Author

Hadji, P., Coleman, R.E., Wilson, C., Powles, T.J., Clézardin, P., Aapro, M., Costa, L., Body, J.-J., Markopoulos, C., Santini, D., Diel, I., Di Leo, A., Cameron, D., Dodwell, D., Smith, I., Gnant, M., Gray, R., Harbeck, N., Thurlimann, B., Untch, M., Cortes, J., Martin, M., Albert, U.-S., Conte, P.-F., Ejlertsen, B., Bergh, J., Kaufmann, M., and Holen, I.

Published
2016
Full Text
View/download PDF

27. 2023 updated MASCC/ESMO consensus recommendations:prevention of nausea and vomiting following high-emetic-risk antineoplastic agents

Author

Herrstedt, Jørn, Celio, L., Hesketh, Pj, Zhang, L., Navari, R., Chan, A., Saito, M., Chow, R., Aapro, M., Herrstedt, Jørn, Celio, L., Hesketh, Pj, Zhang, L., Navari, R., Chan, A., Saito, M., Chow, R., and Aapro, M.

Abstract

Purpose This systematic review updates the MASCC/ESMO recommendations for high-emetic-risk chemotherapy (HEC) published in 2016–2017. HEC still includes cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, and cyclophosphamide in doses of > 1500 mg/m2 and the combination of cyclophosphamide and an anthracycline (AC) in women with breast cancer. Methods A systematic review report following the PRISMA guidelines of the literature from January 1, 2015, until February 1, 2023, was performed. PubMed (Ovid), Scopus (Google), and the Cochrane Database of Systematic Reviews were searched. The literature search was limited to randomized controlled trials, systematic reviews, and meta-analyses. Results Forty-six new references were determined to be relevant. The main topics identified were (1) steroid-sparing regimens, (2) olanzapine-containing regimens, and (3) other issues such as comparisons of antiemetics of the same drug class, intravenous NK1 receptor antagonists, and potentially new antiemetics. Five updated recommendations are presented. Conclusion There is no need to prescribe steroids (dexamethasone) beyond day 1 after AC HEC, whereas a 4-day regimen is recommended in non-AC HEC. Olanzapine is now recommended as a fixed part of a four-drug prophylactic antiemetic regimen in both non-AC and AC HEC. No major differences between 5-HT3 receptor antagonists or between NK1 receptor antagonists were identified. No new antiemetic agents qualified for inclusion in the updated recommendations., Purpose: This systematic review updates the MASCC/ESMO recommendations for high-emetic-risk chemotherapy (HEC) published in 2016–2017. HEC still includes cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, and cyclophosphamide in doses of > 1500 mg/m2 and the combination of cyclophosphamide and an anthracycline (AC) in women with breast cancer. Methods: A systematic review report following the PRISMA guidelines of the literature from January 1, 2015, until February 1, 2023, was performed. PubMed (Ovid), Scopus (Google), and the Cochrane Database of Systematic Reviews were searched. The literature search was limited to randomized controlled trials, systematic reviews, and meta-analyses. Results: Forty-six new references were determined to be relevant. The main topics identified were (1) steroid-sparing regimens, (2) olanzapine-containing regimens, and (3) other issues such as comparisons of antiemetics of the same drug class, intravenous NK1 receptor antagonists, and potentially new antiemetics. Five updated recommendations are presented. Conclusion: There is no need to prescribe steroids (dexamethasone) beyond day 1 after AC HEC, whereas a 4-day regimen is recommended in non-AC HEC. Olanzapine is now recommended as a fixed part of a four-drug prophylactic antiemetic regimen in both non-AC and AC HEC. No major differences between 5-HT3 receptor antagonists or between NK1 receptor antagonists were identified. No new antiemetic agents qualified for inclusion in the updated recommendations.

Published
2023

35. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper

Author

Casali, P.G., Bruzzi, P., Bogaerts, J., Blay, J.-Y., Aapro, M., Adamous, A., Berruti, A., Bressington, J., Bruzzi, B., Capocaccia, R., Cardoso, F., Celis, J.E., Cervantes, A., Ciardiello, F., Claussen, C., Coleman, M., Comis, S., Craine, S., De Boltz, D., De Lorenzo, F., Dei Tos, A.P., Gatta, G., Geissler, J., Giuliani, R., Grande, E., Gronchi, A., Jezdic, S., Jonsson, B., Jost, L., Keulen, H., Lacombe, D., Lamory, G., Le Cam, Y., Leto di Priolo, S., Licitra, L., Macchia, F., Margulies, A., Marreaud, S., McVie, G., Narbutas, S., Oliver, K., Pavlidis, N., Pelouchova, J., Pentheroudakis, G., Piccart, M., Pierotti, M.A., Pravettoni, G., Redmond, K., Riegman, P., Ruffilli, M.P., Ryner, D., Sandrucci, S., Seymour, M., Torri, V., Trama, A., Van Belle, S., Vassal, G., Wartenberg, M., Watts, C., Wilson, A., and Yared, W.

Published
2015
Full Text
View/download PDF

36. Nutrition education in medical schools (NEMS) project: Promoting clinical nutrition in medical schools – Perspectives from different actors

Author

Cuerda, C., primary, Muscaritoli, M., additional, Chourdakis, M., additional, Krznaric, Z., additional, Archodoulakis, A., additional, Gürbüz, S., additional, Berk, K., additional, Aapro, M., additional, Farrand, C., additional, Patja, K., additional, Schneider, S., additional, and Barazzoni, R., additional

Published
2023
Full Text
View/download PDF

37. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Author

Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Biganzoli, L., Blackwell, K.L., Cardoso, M.J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S.H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U.N., Mayer, M., Merjaver, S.D., Nordström, E.B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M.J., Rugo, H., Sledge, G., Thomssen, C., van’t Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., and Winer, E.

Published
2014
Full Text
View/download PDF

45. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Author

Cardoso, F, Costa, A, Senkus, E, Aapro, M, André, F, Barrios, C H, Bergh, J, Bhattacharyya, G, Biganzoli, L, Cardoso, M J, Carey, L, Corneliussen-James, D, Curigliano, G, Dieras, V, El Saghir, N, Eniu, A, Fallowfield, L, Fenech, D, Francis, P, Gelmon, K, Gennari, A, Harbeck, N, Hudis, C, Kaufman, B, Krop, I, Mayer, M, Meijer, H, Mertz, S, Ohno, S, Pagani, O, Papadopoulos, E, Peccatori, F, Penault-Llorca, F, Piccart, M J, Pierga, J Y, Rugo, H, Shockney, L, Sledge, G, Swain, S, Thomssen, C, Tutt, A, Vorobiof, D, Xu, B, Norton, L, and Winer, E

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results